Summary
This study employed a systematic in silico screening approach of over 1500 repurposed compounds combined with preclinical validation to identify therapeutic candidates for multiple sclerosis. Bavisant, a histamine receptor H3 antagonist, emerged from this pipeline and demonstrated promyelinating and neuroprotective activity in both human and rodent in vitro models, as well as in multiple mouse models of demyelination and axonal injury. The findings provide preclinical support for bavisant as a candidate for clinical trials in progressive MS.
Regional applicability
This is fundamental neurobiological and drug discovery research with international participation; findings are directly applicable to MS drug development globally, including in the United Kingdom where MS affects approximately 130,000 people. The work may inform future neuroprotective therapeutic strategies for UK MS patients, particularly those with progressive disease where current treatments are insufficient.
Key measures
Remyelination and neuroprotection outcomes in oligodendroglia and neurons; efficacy in LPC-treated, cuprizone-fed, MOG-induced EAE mice, and human oligodendroglia chimeric mouse models
Outcomes reported
The study identified bavisant, a histamine receptor H3 antagonist, as a therapeutic candidate through in silico screening of 1500+ repurposed compounds followed by validation in rodent and human in vitro assays and mouse demyelination models. Bavisant demonstrated promyelinating and neuroprotective effects across multiple preclinical models of multiple sclerosis.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.